trending Market Intelligence /marketintelligence/en/news-insights/trending/9Cxxjpwj4PItD3YqvikjqA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

XBiotech starts tender offer to buy up to $420M of its common shares

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

XBiotech starts tender offer to buy up to $420M of its common shares

XBiotech Inc. started a tender offer to buy up to $420 million of its common shares at a price of between $30 and $33 apiece.

The Austin, Texas-based biopharmaceutical company said the offer will provide the company's shareholders the opportunity to obtain liquidity with respect to all or a portion of their stock in the company without disrupting XBiotech's stock price.

The offer is subject to certain terms and conditions. The tender offer will expire at 5 p.m., New York City time on Feb. 12 unless the offer is extended.

D.F. King & Co. Inc. will be information agent for the tender offer.

XBiotech develops therapies based on harnessing naturally occurring antibodies from patients with immunity to various diseases.

In December 2019, Johnson & Johnson acquired all rights to XBiotech's experimental anti-inflammatory antibody bermekimab in a $750 million deal. XBiotech was developing bermekimab as a potential treatment for different cancer types; diabetes; cardiovascular diseases; and skin disorders, including atopic dermatitis, or eczema, and hidradenitis suppurativa.